Welcome to our dedicated page for NUGEN MEDICAL DEVICES news (Ticker: NGMDF), a resource for investors and traders seeking the latest updates and insights on NUGEN MEDICAL DEVICES stock.
NuGen Medical Devices Inc. develops needle-free devices for subcutaneous drug delivery, centered on the InsuJet™ system for insulin administration and related consumables. Company news commonly covers commercialization of InsuJet and EziAutoJector® through distributors and pharmacy channels, product availability in markets such as France and the United Kingdom, and medical-device regulatory updates tied to national approvals and licensing.
NuGen updates also include research and development for prefilled and cartridge-based needle-free injection formats, patent activity for Ready-to-Fill COP/COC nozzles and the Prefilled Nozzle platform, annual financial results, and governance changes involving financial reporting functions.
NuGen Medical Devices (NGMDF) announced a non-binding letter of intent dated August 5, 2026 with Sol-Millennium Medical HK to acquire all common shares of Sol-Millennium Canada. The Proposed Transaction is subject to due diligence, board approvals and regulatory clearances before any definitive agreement is signed.
According to NuGen, post-transaction ownership is expected to be about 65% for SolM HK and 35% for current NuGen shareholders, excluding convertible securities. SolM will also provide NuGen with a $1.3 million secured bridge loan at 6% annual interest, maturing five years after the initial advance, with $500,000 advanced after a loan agreement and $800,000 on signing a definitive deal. NuGen expects the transaction to add an operating distribution business, diversify its activities, and support product development, regulatory and market expansion plans, while it negotiates existing debt arrangements to terms acceptable to SolM HK.
NuGen Medical Devices (NGMDF) filed two new patent applications covering high‑efficiency spring charging and automatic dose‑establishment technologies for its future needle‑free drug delivery platforms. These patents, developed at NuGen’s Netherlands innovation hub, complement earlier filings on dual‑spring injection, refill and prefilled nozzle platforms.
According to NuGen, the resulting IP portfolio underpins a three‑part future platform family (Transfer, Refill and Prefilled) aimed at simplifying operation, cutting user training, and enabling patients familiar with insulin pens to adopt needle‑free delivery with comparable ease.
NuGen Medical Devices (OTC:NGMDF) filed a new patent application (P105204NL) for dual-actuator, needle-free injection technology that shapes a multi-phase pressure profile. The design targets a high-pressure piercing phase for skin penetration followed by a lower-pressure delivery phase to support consistency and comfort.
Ex-vivo human tissue testing with Crux Product Design showed delivery depths comparable to conventional needle injections within subcutaneous ranges. The technology is expected to be integrated into NuGen’s InsuJet V6, Refill, and prefilled nozzle platforms, expanding its intellectual property and drug-delivery strategy.
NuGen Medical Devices (OTC:NGMDF) filed a patent application for a Ready-to-Fill COP/COC needle-free injection nozzle that integrates with a reusable auto-injector as a Prefilled Nozzle (PFN) platform. The nozzle targets high-pressure jet injection, 0.5 mL and 1.0 mL formats, and is developed with Gerresheimer to fit existing aseptic fill-finish lines.
Key near-term milestones include sample qualification for preclinical testing by end-2026 and a fixed-dose auto-injector launch planned for 2027.
NuGen Medical Devices (TSXV:NGMDF) temporarily halted sales of certain devices in Canada after its Health Canada licence expired due to an untimely certificate renewal. This lapse is not a regulatory suspension or safety issue. A new licence application has been submitted and the company says communications with Health Canada are ongoing; global operations remain unaffected.
NuGen Medical Devices (TSXV: NGMDF) announced a change in senior finance leadership effective January 31, 2026. Veronique Laberge resigned as Chief Financial Officer and Corporate Secretary and Ajay Mishra was appointed to both roles. The company said Mr. Mishra will assume responsibility for financial reporting and related functions.
NuGen Medical Devices (TSXV: NGMDF) provided a 2025 year-end update outlining R&D, technical, clinical, and commercial progress across its needle-free subcutaneous drug-delivery programs.
Key 2025 achievements include feasibility of a Ready-to-Fill Nozzle, advancement of a next-generation variable-dose jet injector, pressure-profile optimization, prototype progress on a patented refill cartridge system, and development of an animal-use PetJet injector.
Operational expansions included a Netherlands design hub, two MedTech hires in China, clinical team growth in France, Brazil and Malaysia, formation of a Medical Advisory Board, UK launch of the EZIAUTOJECTOR with NHS Drug Tariff approval, and ongoing distributor and payer engagement in Mexico, Asia and Canada.
NuGen Medical Devices (TSXV: NGMD) has achieved a significant milestone as its UK distribution partner, EziAutoJector Ltd, received NHS Drug Tariff approval for its needle-free insulin delivery device. This approval means UK diabetes patients can receive the EziAutoJector device and accessories at no cost through NHS-funded care.
The company has established distribution channels through a major pharmaceutical wholesaler for both high-street and online pharmacies. The initiative includes educational programs targeting healthcare professionals and a direct-to-consumer e-commerce channel. Notably, each patient switching to EziAutoJector eliminates over 1,000 single-use insulin needles annually, supporting NHS environmental and cost-efficiency goals.
NuGen Medical Devices (TSXV: NGMD) has announced the development of a next-generation needle-free injection system featuring innovative internal cartridge technology. The system, protected under international patent WO2021206553, integrates a sterile internal insulin cartridge into their proprietary autoinjector.
The new design eliminates the need for external connectors and manual filling, offering improved safety and ease of use compared to current systems like InsuJet. Key technical features include an internal cartridge integration, backflow control mechanism, and enhanced usability.
Under CEO Liang Lin's leadership, NuGen plans to begin clinical investigations using their current platform while developing the new system. The company aims to produce working prototypes within six months and begin tooling investment in early 2026.
NuGen Medical Devices (TSXV: NGMD) has launched a French e-commerce platform www.insujet.fr for its needle-free insulin delivery device InsuJet. Developed with Sol-Millennium France, the platform offers product information, educational resources, and secure purchasing with optional nurse-led onboarding support.
The launch addresses a significant market opportunity in France, where 4.33 million people (6.3% of the population) lived with diabetes in 2022. Diabetes-related reimbursements in France increased from €7.6 billion in 2015 to over €10 billion in 2022. With 92% of Type 2 diabetes patients delaying insulin start due to needle anxiety, InsuJet aims to improve treatment adoption and reduce healthcare costs.